Neoclarityn

Neoclarityn contains desloratadine, a non-sedating second-generation antihistamine used for the symptomatic relief of allergic rhinitis and chronic idiopathic urticaria.

Desloratadine is the active metabolite of loratadine and provides potent, long-lasting histamine H1-receptor blockade without significant central nervous system penetration, meaning it is unlikely to cause drowsiness at recommended doses.

In allergic rhinitis, Neoclarityn relieves sneezing, runny or itchy nose, nasal congestion, and itchy, watering eyes.

In chronic urticaria, it reduces the frequency and severity of hives and the associated itching.

The medication is taken once daily and provides symptom control for a full 24 hours, making it a convenient option for long-term allergy management.

Neoclarityn is available as tablets, an orodispersible tablet, and an oral solution, catering to adults, adolescents, and children from as young as one year of age.

It can be taken with or without food and does not interact significantly with most common medications.

Take one 5 mg tablet once daily, with or without food. Swallow the tablet whole with water.

For the orodispersible formulation, place the tablet on the tongue and allow it to dissolve; swallowing with water is optional.

For children, the oral solution is dosed by age and weight as directed by the prescriber.

Neoclarityn may be taken on an ongoing basis during allergy seasons or year-round for chronic urticaria. Consistency in daily dosing provides the best symptom control.

Adults and adolescents over 12 years: 5 mg once daily. Children aged 6 to 11 years: 2.5 mg once daily (oral solution or half a 5 mg orodispersible tablet). Children aged 1 to 5 years: 1.

25 mg once daily (oral solution). No dose adjustment is normally required in the elderly. Patients with severe renal impairment should use desloratadine with caution as clearance may be reduced.

Neoclarityn is generally very well tolerated. Common side effects in adults include headache, dry mouth, and fatigue, each occurring in a small percentage of users.

In children, the most frequently reported effects are diarrhoea and insomnia. Drowsiness is uncommon at the recommended dose but may occur in susceptible individuals.

Rare effects include palpitations, tachycardia, raised liver enzymes, and hypersensitivity reactions such as rash, urticaria, or anaphylaxis.

Very rarely, hallucinations and seizures have been reported.

Although desloratadine is classified as non-sedating, some individuals may experience drowsiness, particularly at the start of treatment.

Exercise caution with driving or operating machinery until you know how the medication affects you. Use with care in patients with severe renal impairment.

Inform your prescriber if you have epilepsy or are at risk of seizures. If you have phenylketonuria, note that some orodispersible formulations may contain aspartame.

Neoclarityn is contraindicated in individuals with known hypersensitivity to desloratadine, loratadine, or any excipient in the formulation.

No other absolute contraindications exist, but dose adjustment or monitoring may be required in severe renal or hepatic impairment.